Chemicals - Specialty
Compare Stocks
4 / 10Stock Comparison
GEVO vs VERO vs INMD vs AMTX
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Devices
Medical - Devices
Oil & Gas Refining & Marketing
GEVO vs VERO vs INMD vs AMTX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Chemicals - Specialty | Medical - Devices | Medical - Devices | Oil & Gas Refining & Marketing |
| Market Cap | $493M | $499K | $882M | $213M |
| Revenue (TTM) | $174M | $59M | $375M | $209M |
| Net Income (TTM) | $-11M | $-55M | $87M | $-74M |
| Gross Margin | 23.4% | 64.4% | 77.8% | 3.4% |
| Operating Margin | -4.6% | -59.0% | 21.3% | -13.4% |
| Forward P/E | — | — | 9.6x | — |
| Total Debt | $168M | $43M | $13M | $318M |
| Cash & Equiv. | $1M | $4M | $303M | $5M |
GEVO vs VERO vs INMD vs AMTX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Gevo, Inc. (GEVO) | 100 | 157.4 | +57.4% |
| Venus Concept Inc. (VERO) | 100 | 0.1 | -99.9% |
| InMode Ltd. (INMD) | 100 | 95.0 | -5.0% |
| Aemetis, Inc. (AMTX) | 100 | 390.0 | +290.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: GEVO vs VERO vs INMD vs AMTX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
GEVO is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 8.5%, EPS growth 58.8%, 3Y rev CAGR 415.1%
- 8.5% revenue growth vs AMTX's -22.3%
VERO lags the leaders in this set but could rank higher in a more targeted comparison.
INMD carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 1.04
- 105.0% 10Y total return vs AMTX's 31.1%
- Lower volatility, beta 1.04, Low D/E 1.9%, current ratio 9.88x
- Beta 1.04, current ratio 9.88x
AMTX is the clearest fit if your priority is momentum.
- +140.0% vs VERO's -88.5%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 8.5% revenue growth vs AMTX's -22.3% | |
| Quality / Margins | 23.3% margin vs VERO's -92.8% | |
| Stability / Safety | Beta 1.04 vs GEVO's 1.64, lower leverage | |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | +140.0% vs VERO's -88.5% | |
| Efficiency (ROA) | 11.8% ROA vs VERO's -88.6%, ROIC 13.5% vs -39.8% |
GEVO vs VERO vs INMD vs AMTX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
GEVO vs VERO vs INMD vs AMTX — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
INMD leads in 3 of 6 categories
VERO leads 1 • GEVO leads 0 • AMTX leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
INMD leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
INMD is the larger business by revenue, generating $375M annually — 6.4x VERO's $59M. INMD is the more profitable business, keeping 23.3% of every revenue dollar as net income compared to VERO's -92.8%. On growth, GEVO holds the edge at +47.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $174M | $59M | $375M | $209M |
| EBITDAEarnings before interest/tax | $18M | -$31M | $81M | -$21M |
| Net IncomeAfter-tax profit | -$11M | -$55M | $87M | -$74M |
| Free Cash FlowCash after capex | -$35M | -$21M | $91M | -$38M |
| Gross MarginGross profit ÷ Revenue | +23.4% | +64.4% | +77.8% | +3.4% |
| Operating MarginEBIT ÷ Revenue | -4.6% | -59.0% | +21.3% | -13.4% |
| Net MarginNet income ÷ Revenue | -6.6% | -92.8% | +23.3% | -35.4% |
| FCF MarginFCF ÷ Revenue | -19.9% | -35.2% | +24.2% | -18.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +47.5% | -8.2% | +5.3% | +27.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +3.8% | -8.5% | -30.8% | +29.8% |
Valuation Metrics
VERO leads this category, winning 2 of 4 comparable metrics.
Valuation Metrics
On an enterprise value basis, INMD's 6.9x EV/EBITDA is more attractive than GEVO's 102.1x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $493M | $498,989 | $882M | $213M |
| Enterprise ValueMkt cap + debt − cash | $659M | $39M | $593M | $526M |
| Trailing P/EPrice ÷ TTM EPS | -14.50x | -0.00x | 9.73x | -2.44x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 9.64x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | 0.98x | — |
| EV / EBITDAEnterprise value multiple | 102.12x | — | 6.88x | — |
| Price / SalesMarket cap ÷ Revenue | 3.07x | 0.01x | 2.38x | 1.02x |
| Price / BookPrice ÷ Book value/share | 1.01x | 0.07x | 1.33x | — |
| Price / FCFMarket cap ÷ FCF | — | — | 10.46x | — |
Profitability & Efficiency
INMD leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
INMD delivers a 13.3% return on equity — every $100 of shareholder capital generates $13 in annual profit, vs $-17 for VERO. INMD carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to VERO's 15.16x. On the Piotroski fundamental quality scale (0–9), VERO scores 5/9 vs INMD's 3/9, reflecting solid financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | -2.4% | -17.4% | +13.3% | — |
| ROA (TTM)Return on assets | -1.7% | -88.6% | +11.8% | -29.3% |
| ROICReturn on invested capital | -2.8% | -39.8% | +13.5% | -70.3% |
| ROCEReturn on capital employed | -3.1% | -54.2% | +12.1% | -19.0% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 5 | 3 | 4 |
| Debt / EquityFinancial leverage | 0.36x | 15.16x | 0.02x | — |
| Net DebtTotal debt minus cash | $166M | $39M | -$289M | $313M |
| Cash & Equiv.Liquid assets | $1M | $4M | $303M | $5M |
| Total DebtShort + long-term debt | $168M | $43M | $13M | $318M |
| Interest CoverageEBIT ÷ Interest expense | -0.04x | -9.69x | — | -0.27x |
Total Returns (Dividends Reinvested)
Evenly matched — GEVO and INMD and AMTX each lead in 2 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in INMD five years ago would be worth $3,613 today (with dividends reinvested), compared to $9 for VERO. Over the past 12 months, AMTX leads with a +140.0% total return vs VERO's -88.5%. The 3-year compound annual growth rate (CAGR) favors GEVO at 18.2% vs VERO's -79.4% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | -1.5% | -82.3% | -5.9% | +96.2% |
| 1-Year ReturnPast 12 months | +88.0% | -88.5% | -2.1% | +140.0% |
| 3-Year ReturnCumulative with dividends | +65.0% | -99.1% | -60.2% | +37.4% |
| 5-Year ReturnCumulative with dividends | -65.2% | -99.9% | -63.9% | -76.1% |
| 10-Year ReturnCumulative with dividends | -98.6% | -100.0% | +105.0% | +31.1% |
| CAGR (3Y)Annualised 3-year return | +18.2% | -79.4% | -26.4% | +11.2% |
Risk & Volatility
INMD leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
INMD is the less volatile stock with a 1.04 beta — it tends to amplify market swings less than GEVO's 1.64 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. INMD currently trades 83.2% from its 52-week high vs VERO's 2.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.64x | 1.43x | 1.04x | 1.46x |
| 52-Week HighHighest price in past year | $2.97 | $12.93 | $16.74 | $3.80 |
| 52-Week LowLowest price in past year | $1.01 | $0.26 | $12.72 | $1.22 |
| % of 52W HighCurrent price vs 52-week peak | +68.4% | +2.1% | +83.2% | +82.1% |
| RSI (14)Momentum oscillator 0–100 | 53.5 | 42.9 | 39.8 | 58.2 |
| Avg Volume (50D)Average daily shares traded | 4.5M | 9K | 804K | 1.8M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: GEVO as "Buy", INMD as "Buy", AMTX as "Buy". Consensus price targets imply 72.4% upside for GEVO (target: $4) vs -43.9% for AMTX (target: $2).
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — | Buy | Buy |
| Price TargetConsensus 12-month target | $3.50 | — | $16.00 | $1.75 |
| # AnalystsCovering analysts | 14 | — | 11 | 7 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +14.5% | 0.0% |
INMD leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). VERO leads in 1 (Valuation Metrics). 1 tied.
GEVO vs VERO vs INMD vs AMTX: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is GEVO or VERO or INMD or AMTX a better buy right now?
For growth investors, Gevo, Inc.
(GEVO) is the stronger pick with 849. 3% revenue growth year-over-year, versus -22. 3% for Aemetis, Inc. (AMTX). InMode Ltd. (INMD) offers the better valuation at 9. 7x trailing P/E (9. 6x forward), making it the more compelling value choice. Analysts rate Gevo, Inc. (GEVO) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — GEVO or VERO or INMD or AMTX?
Over the past 5 years, InMode Ltd.
(INMD) delivered a total return of -63. 9%, compared to -99. 9% for Venus Concept Inc. (VERO). Over 10 years, the gap is even starker: INMD returned +105. 0% versus VERO's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — GEVO or VERO or INMD or AMTX?
By beta (market sensitivity over 5 years), InMode Ltd.
(INMD) is the lower-risk stock at 1. 04β versus Gevo, Inc. 's 1. 64β — meaning GEVO is approximately 58% more volatile than INMD relative to the S&P 500. On balance sheet safety, InMode Ltd. (INMD) carries a lower debt/equity ratio of 2% versus 15% for Venus Concept Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — GEVO or VERO or INMD or AMTX?
By revenue growth (latest reported year), Gevo, Inc.
(GEVO) is pulling ahead at 849. 3% versus -22. 3% for Aemetis, Inc. (AMTX). On earnings-per-share growth, the picture is similar: Gevo, Inc. grew EPS 58. 8% year-over-year, compared to -869. 0% for Venus Concept Inc.. Over a 3-year CAGR, GEVO leads at 415. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — GEVO or VERO or INMD or AMTX?
InMode Ltd.
(INMD) is the more profitable company, earning 25. 3% net margin versus -72. 5% for Venus Concept Inc. — meaning it keeps 25. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INMD leads at 23. 0% versus -41. 9% for VERO. At the gross margin level — before operating expenses — INMD leads at 78. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is GEVO or VERO or INMD or AMTX more undervalued right now?
Analyst consensus price targets imply the most upside for GEVO: 72.
4% to $3. 50.
07Which pays a better dividend — GEVO or VERO or INMD or AMTX?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is GEVO or VERO or INMD or AMTX better for a retirement portfolio?
For long-horizon retirement investors, InMode Ltd.
(INMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 04), +105. 0% 10Y return). Gevo, Inc. (GEVO) carries a higher beta of 1. 64 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (INMD: +105. 0%, GEVO: -98. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between GEVO and VERO and INMD and AMTX?
These companies operate in different sectors (GEVO (Basic Materials) and VERO (Healthcare) and INMD (Healthcare) and AMTX (Energy)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: GEVO is a small-cap high-growth stock; VERO is a small-cap quality compounder stock; INMD is a small-cap deep-value stock; AMTX is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.